Achievements
Proprietary P.L.E.A.S.E.® platform technology
• Pantec Biosolutions has completed the development of a proprietary, laser-based
core technology platform with clear USPs that allows a vast number of applications.
This offers enormous future growth potential.
• Pantec Biosolutions’ technology provides for international licensing opportunities to
generate revenues in the short term. Several pharmaceutical/biotechnology
companies have already confirmed their interest.
Financially attractive, low risk investment
• Major milestones, including the completion of Phase I clinical studies, have been
successfully achieved by the Company.
• Commercialization of the Company’s devices is planned for the next few years.
Only a small number of infertility clinics need to adopt the new P.L.E.A.S.E. treatment
in order to generate positive cash flows and amortize development costs.
• This provides for a quick time to market and low risk to market for potential
investors while offering significant upside potential.
Focus on rapidly growing IVF market
• The market most relevant for Pantec Biosolutions - In Vitro Fertilisation (IVF) – is a
highly attractive specialty pharma market and set for double-digit growth for the
years to come.
• The Company holds a leading first-mover position with significant competitive
advantages including successful proof-of-concept studies, a unique IP position
and an excellent R&D network.
Multi-step approach “IVF first, other applications later” for commercializing a breakthrough technology
• Pantec Biosolutions development and commercialization strategy is currently focused
on In Vitro Fertilization (IVF) with a one-stop package solution (device and patch).
• Additional applications, e.g. dermatology, are currently followed with a partnering
strategy to leverage the Company’s existing technology platform.
• This strategy will provide the Company with profound knowledge and an efficient
proof of concept which will enable the development of further applications in a
time- and cost-efficient manner.
Know-how of experienced management team
• Pantec Biosolutions’ management team has in-depth knowledge of the IVF and
transdermal drug delivery market as well as customer requirements.
• The management team successfully raised capital in an amount of nearly
CHF 12 m in several financing rounds so far.
• Pantec Biosolutions’ management team shows a high degree of identification
with the Company and is strongly committed to further develop and grow the
Company’s business activities.
Exit potential
• Pantec Biosolutions will represent an attractive acquisition target following the
completion and commercialization of its IVF applications and also successful
partnering with companies interested in combining their drugs with the
intraepidermal system of Pantec Biosolutions.
• Given supportive capital markets, there would also be the potential for an IPO
in the mid- to long-term perspective.
| 
